HOME ABOUT US TECHNOLOGY PRODUCTS CONTACT US  
 
       
 
 

News
   
  About Us
  Career Opportunities
  Directions
  News
     


April 3, 2008
BioHelix Corporation was awarded three NIH grants to develop diagnostic assays based on its proprietary HDA technologies.


BioHelix announced today that it was awarded three Small Business Innovative Research (SBIR) grants from the National Institutes of Health. Two phase I SBIR grants for the development of diagnostic assays based on BioHelix "instrument-free" IsoAmp platform. One supports the development of IsoAmp Group B Strep assay for detecting colonization by Streptococcus agalactiae in pregnant women and one supports the development of low-cost IsoAmp HIV assay. In addition, the company also receives a 3-year phase 2 award for developing Herpes virus typing assay for detecting genital herpes based on an isothermal realtime detection platform. The SBIR awards will enable BioHelix to continue developing innovative isothermal amplification technologies for use in clinical diagnostics.
 
<<Back to News
         
Privacy, Limitation, Warranty, Disclaimer